Instant International
Written by: Hong Yilin
2021-07-06 03:07
The last update date: 2021-07-06 03:07
A study published by the University of Chile on July 2 showed that the novel coronavirus pneumonia (COVID-19) vaccine developed by Sinovac Biotech is less effective in preventing the variant virus strains Lambda, Gamma and Alpha.
The study published on MedRxiv showed that the effectiveness of Kexing vaccine against Lambda was reduced by 3.05 times, and its effectiveness against the mutant virus Gamma was reduced by 2.33 times, while its effectiveness against the mutant virus Alpha was reduced by 2.03 Times.
+2
+2
+2
The virologist Ricardo Soto who led the study explained that most vaccines are developed with reference to the new coronavirus provirus, and there is no guarantee that they will respond to the new variant virus.
Soto said that the mutation of the new coronavirus will change the spike protein (Spike Protein). The new feature of this protein gives the virus the power to evade antibodies.
Singapore's epidemic prevention restrictions are relaxed, but those who vaccinate China's Kexing vaccine still need to be tested
China Kexing Vaccine｜Beijing refutes the alleged ineffectiveness of vaccines: pure hype
China Kexing Vaccine | Singapore Expert Group Says Need to Provide Further Data for Evaluation
Kexing Vaccine｜Brazil Study: New Coronary Pneumonia Deaths Reduced by 95% after Widespread Vaccination
The expert concluded: "This may explain why people who have received 2 doses of Koxing vaccine will become seriously ill or die after being infected with the new crown. Some things should (and therefore) be confirmed."
China Kexing's new crown pneumonia new crown vaccine global epidemic
